美国药物基因组学实施进展:障碍消解与剩余挑战
本文为叙述性综述,基于作者经验梳理美国药物基因组学临床实施在公平与包容、指南与证据、监管、支付与保险、检测质量、电子健康记录、医患教育七个领域的现存障碍。文章回顾既往成功与挑战,并提出扩大推荐范围、制定临床决策支持工具标准及加强教育等解决方案。
要点
- CPIC 早年在四领域识别的实施障碍已部分消解,但七领域障碍仍阻碍推广。
- 剩余障碍涵盖公平包容、指南证据、监管、支付、检测质量、电子健康记录与教育。
- 建议扩大药物基因组学推荐范围、规范临床决策支持工具设计并加强教育。
核心结论
- 美国临床药物基因组学检测实施已取得进展,但七个领域的剩余障碍仍限制其更广泛采用。
研究设计与样本
- 叙述性综述,基于作者专业经验识别并描述美国药物基因组学实施的七领域障碍。
主要发现
- CPIC 于 2009 和 2010 年的调查在四个领域识别了阻碍临床药物基因组学检测广泛采用的障碍。
- 当前七领域障碍包括公平与包容、指南与支持证据、监管机构监督、支付方覆盖与保险、高质量检测可及性、电子健康记录、医患教育。
临床怎么用
- 临床实施需关注七领域障碍,并参考扩大推荐范围、临床决策支持工具设计标准与 broader 教育等提出的解决方案。
局限性
- 本文为叙述性综述,障碍识别基于作者经验与专业判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing. These are presented verbatim as: (i) absence of a definition of the processes required to interpret genotype information and to translate genetic information into clinical actions; (ii) need for recommended drug/gene pairs to implement clinically now; (iii) clinician resistance to consider pharmacogenetic information at the bedside; and (iv) concerns about test costs and reimbursement. Over time, many of these challenges have been overcome, and clinical pharmacogenetic testing has subsequently reached broader implementation. Despite this progress, several barriers remain that block further adoption. This narrative review used authors' expertise and experience to identify and describe current barriers to pharmacogenetic implementation across seven domains in the United States: equity and inclusion; guidelines and supporting evidence; regulatory agency oversight; payer coverage and insurance; availability of quality pharmacogenetic tests; electronic health records; and provider and patient education. Within each domain, it revisits past successes and challenges and explores remaining barriers. We also propose solutions to address ongoing challenges across these domains, including further expansion of recommendations beyond pharmacogenetic-specific guidelines, standards for designing clinical decision support tools, and broader pharmacogenetics education. Addressing these remaining obstacles directs work to enable broader adoption of clinical pharmacogenetic implementation to ultimately improve patient outcomes.
引用
- Smith DM, Douglas MP, Aquilante CL, et al. Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. Clin Pharmacol Ther. 2025. PMID: 40468601. doi:10.1002/cpt.3736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。